China’s biotech industry saw a dip in deal volume and value for innovative drugs in July after a rebound in the previous month. Chinese biotech companies made a total of 10 deals, with disclosed deal value amounting to over $1.5 billion.
China’s pursuit of innovative oncology drugs has kept Chinese regulators busy in July, as they granted the first marketing approvals to two foreign drugs and accepted NDAs for nine more new ones.
LianBio Acquires Three Potential FIC Therapies for Cancer and IBD.